SEATTLE & IRVINE, Calif.–(BUSINESS WIRE)–Visus Therapeutics Inc., a clinical-stage pharmaceutical company developing innovative ophthalmic therapies to improve the vision of people around the world, today announced the appointment of Julia Williams , an eye care industry veteran, noted vice president of clinical and medical affairs. The Company also announced the expansion of its Irvine co-headquarters at the University of California-Irvine Research Park, including the establishment of a research and development facility with a state-of-the-art laboratory. The Irvine expansion increases the Company’s office space by 33% and serves as a hub for R&D, clinical and commercial activities in support of the Company’s growth strategy as it begins Phase 3 clinical trials of its lead presbyopia treatment candidate, BRIMOCHOL ™.
“As we continue to invest in our research, development and commercial capabilities, expanding our joint Irvine headquarters was a natural progression to drive our growth strategy for 2022 and beyond,” said Ben Bergo, co-founder and chief executive officer of Visus -therapeutics. “This expansion provides the critical infrastructure needed to attract renowned talent and advance our diverse pipeline of ophthalmic therapies that could potentially transform the standard of care for diseases that compromise vision.”
The addition of Ms. Williams to the Visus leadership team strengthens Visus’ capabilities in clinical trial design and execution and medical affairs strategy. With more than 25 years of ophthalmic experience in the fields of retina, glaucoma, dry eye and cornea/external diseases, she previously held senior management positions at Aerie Pharmaceuticals, Allergan, Bausch & Lomb and Heidelberg Engineering. In these roles, Ms. Williams has built and successfully led multidisciplinary teams across marketing, clinical and medical affairs to support more than 15 successful product launches, including Lumigan® (Bimatoprost), Combigan® (brimonidine tartrate/timolol)§Ozurdex® (Dexamethasone intravitreal implant)βXen® gel stentaRhopressa® (Netarsudil)* and Rocklatan® (Netarsudil/Latanoprost).† She has designed and conducted over 25 clinical studies, resulting in over 40 articles, book chapters and presentations in the peer-reviewed ophthalmic literature as author or co-author.
“I am delighted to welcome Julia to the Visus leadership team. Her extensive experience across such a broad spectrum of ophthalmic indications and strong leadership record in medical and clinical matters reinforces our clinical and scientific expertise at a pivotal moment for our company,” said Rhett Schiffman, MD, MS, MHSA, co-founder, chief medical officer and Head of Research and Development at Visus Therapeutics. “As we prepare to begin Phase 3 clinical trials for BRIMOCHOL™, I am confident that Julia will make an extremely valuable contribution to this program and the entire portfolio of ophthalmic candidates.”
About Vision Therapeutics
Visus Therapeutics, with offices in Seattle, Washington and Irvine, California, is a clinical-stage pharmaceutical company focused on developing innovative ophthalmic therapies to improve the vision of people around the world. The company is developing novel miotic formulations for once-daily eye drops to correct near vision loss associated with presbyopia. In parallel, Visus Therapeutics is focused on advancing its pipeline of early-stage ophthalmic product candidates with applications in ocular surface disease, glaucoma and age-related macular degeneration. For more information, visit: www.visustx.com and follow us on LinkedIn, Twitter (@VisusTx) and Instagram.
§Combigan® and βOzurdex® are registered trademarks of Allergan, Inc, an AbbVie company.
aXen® is a registered trademark of AqueSys, Inc., an AbbVie company.
*Rhopressa® and † Rocklatan® are registered trademarks of Aerie Pharmaceuticals, Inc.